Veerhealth Care Ltd — Important, 25-02-2026: Company Update

Veerhealth Care has submitted an investor presentation highlighting significant operational advancements and financial growth. The company received USFDA approval for its registered Drug (OTC) products in June 2025, enabling exports to the U.S. and positioning it for global expansion. Quarterly revenue grew to 7.26 Cr in Q3 FY26, with comprehensive income reaching 0.40 Cr. Annual revenue for FY24-25 was 16.67 Cr. Future projections anticipate net sales of 30.10 Cr in FY25-26, rising to 97.15 Cr by FY27-28, driven by expanded USFDA-compliant facilities and new client onboarding. The company also launched a plastic manufacturing division for backward integration.